浏览全部资源
扫码关注微信
1.广东省科学院测试分析研究所(中国广州分析测试中心),广东省化学测量与应急检测技术重点实验室,广东省中药质量安全工程技术研究中心,广州 510070
2.新加坡国立大学 理学院生物科学系,新加坡 117558
罗辉泰,副研究员,研究方向:色谱-质谱分析技术应用研究,E-mail:luohuitai@qq.com
收稿日期:2025-03-18,
修回日期:2025-04-30,
录用日期:2025-04-30,
纸质出版日期:2025-07-15
移动端阅览
梁梓洋,许锦峰,康怀腾,罗毅,梁韵蕊,张伟川,罗辉泰,黄芳.气相色谱-串联质谱法测定司美格鲁肽原料药中残留缩合剂及催化剂[J].分析测试学报,2025,44(07):1371-1377.
LIANG Zi-yang,XU Jin-feng,KANG Huai-teng,LUO Yi,LIANG Yun-rui,ZHANG Wei-chuan,LUO Hui-tai,HUANG Fang.Determination of Residual Condensation Agents and Catalyst in Semaglutide Active Pharmaceutical Ingredient by Gas Chromatography-Tandem Mass Spectrometry[J].Journal of Instrumental Analysis,2025,44(07):1371-1377.
梁梓洋,许锦峰,康怀腾,罗毅,梁韵蕊,张伟川,罗辉泰,黄芳.气相色谱-串联质谱法测定司美格鲁肽原料药中残留缩合剂及催化剂[J].分析测试学报,2025,44(07):1371-1377. DOI: 10.12452/j.fxcsxb.250318203.
LIANG Zi-yang,XU Jin-feng,KANG Huai-teng,LUO Yi,LIANG Yun-rui,ZHANG Wei-chuan,LUO Hui-tai,HUANG Fang.Determination of Residual Condensation Agents and Catalyst in Semaglutide Active Pharmaceutical Ingredient by Gas Chromatography-Tandem Mass Spectrometry[J].Journal of Instrumental Analysis,2025,44(07):1371-1377. DOI: 10.12452/j.fxcsxb.250318203.
该文基于气相色谱-串联质谱法(GC-MS/MS),建立了司美格鲁肽原料药(APT)中残留缩合剂N,N'-二异丙基碳二亚胺(DIC)、N,N'-二环己基碳二亚胺(DCC)及催化剂N,N'-二甲氨基吡啶(DMAP)的分析方法。司美格鲁肽原料药经乙腈提取后,以Agilent CP-Volamine色谱柱(30 m × 0.32 mm)进行色谱分离,在电子轰击电离源(EI)下以多反应监测(MRM)模式检测,外标法定量。结果表明,目标化合物在10~500 ng/mL范围呈良好线性关系,相关系数(
r
2
)为0.998 8~0.999 9,方法检出限为0.1~0.5 μg/g,定量下限均为1.0 μg/g,平均加标回收率(
n
=9)为97.6%~99.2%,仪器精密度及方法重复性、稳定性、耐用性的相对标准偏差(RSD)均小于6.0%。对13批次司美格鲁肽原料药进行检测,其中1批次检出DMAP,含量为1.3 μg/g。该方法具有方便、准确的优点,可为司美格鲁肽原料药的质量控制提供技术支撑。
A method was established based on gas chromatography-tandem mass spectrometry(GC-MS/MS) to analyze the residual condensing agents N,N'-diisopropylcarbodiimide(DIC) and
N
,
N
'-dicyclohexylcarbodiimide(DCC),and catalyst N,N'-dimethylaminopyridine(DMAP) in semaglutide active pharmaceutical ingredient(API). After extraction with acetonitrile,sample were separated on an Agilent CP-Volamine column(30 m × 0.32 mm),detected in electron impact ionization source(EI) with multiple reaction monitoring(MRM) mode and quantified by the external standard calibration. Target compounds exhibited excellent linearities in the concentration ranges of 10-500 ng/mL,with correlation coefficients(
r
2
) of 0.998 8-0.999 9. The limits of detection were 0.1-0.5 μg/g,while the limits of quantitation were all 1.0 μg/g. The average recoveries(
n
=9) of target compounds were 97.6%-99.2%,while relative standard deviations(RSDs) for precision,repeatability,stability,and robustness were all below 6.0%,indicating good method reliability. Thirteen batches of semaglutide API
were detected,and a positive sample was found with DMAP content of 1.3 μg/g. The method established in this study offers the advantages of convenience and high accuracy,providing reliable technical support for quality control of semaglutide API.
Bergmann N C , Davies M J , Lingvay I , Knop F K . Diabetes,Obes . Metab. , 2023 , 25 ( 1 ): 18 - 35 .
Liu X B , Zhang N , Gu X T , Qin Y H , Song D , Zhang L , Ma S T . ACS Comb. Sci. , 2020 , 22 ( 12 ): 821 - 825 .
Peng D Z , Li Y , Si L L , Zhu B , Wu P , Li Y B , Tang D F , Liu Y , Zhang Y X . Protein Expression Purif. , 2024 , 219 : 106477 .
Sun J G , Zhou Z C , Xia L Y . J. Cangzhou Normal Univ. (孙继国,周自成,夏玲远. 沧州师范学院学报) , 2014 , 30 ( 1 ): 49 - 53 .
Poesen N , Moor A , Busschots A , Dooms‐Goossens A . Contact Dermatitis , 1995 , 32 ( 6 ): 368 - 369 .
Surh I , Behl M , Elmore S A , Chhabra R S . Cutaneous Ocul . Toxicol. , 2012 , 31 ( 3 ): 177 - 187 .
Nzama H , Manne S R , Marder O , Orosz G , de la Torre B G , Albericio F . Green Chem. Lett. Rev. , 2024 , 17 ( 1 ): 2392826 .
Marrs T C , Scawin J , Swanston D W . Toxicology , 1984 , 31 ( 2 ): 165 - 173 .
Du Y , Chen L , Li L , Zhou J , Lü L . J. Pharm. Pract. (杜毅,陈磊,李玲,周瑾,吕磊. 药学实践杂志), 2018 , 36 ( 5 ): 446 - 449 .
Meier J J . Front. Endocrinol. , 2021 , 12 : 645617 .
Yang X D , Yang Y Y . Drug Des. Dev. Ther. , 2024 , 18 : 2555 - 2570 .
ICH M 7 (R2) Guideline on Assessment and Control of DNA Reactive(mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk . International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use ,2023.
Chinese Pharmacopoeia Commission . Pharmacopoeia of the People’s Republic of China 2020(国家药典委员会 . 中华人民共和国药典(2020年版) ) , China Medical Science Press , 2020 .
Zhang K J , Zhao Y . Shandong Chem. Ind. (张可君 , 赵毅 . 山东化工) , 1998 ,( 5 ): 40 - 41 .
Shaanxi HuiKang Bio-Tech Co. , Ltd. . China Patent(陕西慧康生物科技有限责任公司 . 中国专利) ,CN 115406979 . 2022-11-29 .
Hybio Pharmaceutical Co. , Ltd. . China Patent(深圳翰宇药业股份有限公司 . 中国专利) ,CN 106153748 A . 2016-11-23 .
Li Y L , Wu J J , Li J , Li C H , Xue M J . Chin. J. Anal. Lab. (李永利,吴建军,李杰,李春华,薛民杰. 分析试验室) , 2025 . https://link.cnki.net/urlid/11.2017.TF.20241218.1049.025 https://link.cnki.net/urlid/11.2017.TF.20241218.1049.025 .
Liu X Q , Gu X , Ni W F , Tao Q F , Zheng J Q . Chin. J. Mod. Appl. Pharm. (刘小勤,顾霄,倪维芳,陶巧凤,郑金琪. 中国现代应用药学), 2024 , 41 ( 9 ): 1238 - 1241 .
Guo C C , Wen S S , Wang W J , Zhang L Y , Zhang X H , Li L , Niu C , Xu Y W . Chin. J. Anal. Lab. (郭常川,文松松,王维剑,张连义,张小涵,李琳,牛冲,徐玉文. 分析试验室), 2024 , 43 ( 12 ): 1679 - 1683 .
Williams D B G , Lawton M . J. Org. Chem. , 2010 , 75 ( 24 ): 8351 - 8354 .
Liu L L , Zuo T T , Zan K , Jin H Y , Ma S C . Chin. Pharm. J. (刘丽娜,左甜甜,昝珂,金红宇,马双成. 中国药学杂志), 2024 , 59 ( 8 ): 694 - 702 .
Zhang Q Y , Luo H T , Liao J T , Huang F , Liang W W , Wu H Q . J. Instrum. Anal. (张秋炎,罗辉泰,廖均涛,黄芳,梁维维,吴惠勤. 分析测试学报), 2025 , 44 ( 2 ): 211 - 220 .
Yudthavorasit S , Meecharoen W , Leepipatpiboon N . Food Control , 2015 , 48 : 25 - 32 .
Chen K X , Xiao M F , Lin J , Chen H F , Lin K . Chin. J. Publ. Health Eng. (陈柯星,肖明发,林捷,陈华峰,林侃. 中国卫生工程学), 2024 , 23 ( 5 ): 602 - 606 .
0
浏览量
26
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构